Syros Pharmaceuticals
Watertown
About Syros Pharmaceuticals
Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $620.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2023)
- Ticker: nasdaq:SYRS
- Website: syros.com
- Phone: (617) 744-1340
Industries & Categories
Biotechnology, Genetics, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/syros-pharmaceuticals-47078 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.